Peru Reliance Pathway: Reference-Country Approvals and DIGEMID Review 2026

Regulatory information verified as of October 29, 2026

1. Key takeaways

The value of reference-country approvals in Peru is reliance-type evidence, not mutual recognition: approvals from EMA, WHO prequalification (WHO PQ) and the authorities of countries of high sanitary surveillance can shorten the argumentation chain, but the decision remains with DIGEMID, and local technical documentation, the essential-principles conformity checklist and Spanish-language materials cannot be reduced by a single item. The valid boundary of that evidentiary value is triple identity: the same product, the same intended use, the same manufacturing site. If any of the three breaks, the weight of the reference-country approval drops immediately. The specific article numbers behind these acceptance rules are pending verification; official publications prevail. The operating conclusion is simple: reference-country evidence reduces review intensity, never the dossier itself, and every difference against the reference approval must be declared, argued and documented before submission.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight 1: the mechanical difference between reliance and mutual recognition determines the attitude toward local documents.

Mutual recognition transfers part of the decision-making power to the reference-country authority; reliance means the domestic authority accepts the output of the overseas review while retaining independent judgment. Peru operates the latter form for device registration: reference-country approvals enter the dossier as supporting material, while the essential-principles conformity checklist established by D.S. N° 003-2020-SA, published on 2020-02-06, and the Class II–IV technical reports must still be compiled locally. The consequence of mistaking reliance for mutual recognition is an under-built dossier — submitting a compressed package of a CE certificate plus an instructions leaflet, and being returned inside the 66 working days clock when the remaining time is no longer enough to rebuild a complete file.

Insight 2: triple identity is the switch for acceptance, and the break points occur at predictable positions.

A reference-country approval has value because the reviewer can reasonably presume that another mature jurisdiction has already substantively reviewed the same object. That presumption fails the moment identity fails: an expanded model range, an intended-use statement rewritten for the local market, or a changed manufacturing site or outsourced key process all dissolve it. The most frequent break point is the localization of indications wording to suit the sales channel — the commercial side sees a wording adjustment, while the review side sees a substantive deviation from the reference-country approval documents. Managing expected-use language as a controlled item, with formal justification for every deviation, is what keeps the presumption alive through review.

Insight 3: WHO PQ and national approvals are not equivalent.

The output of EMA and of the authorities of countries of high sanitary surveillance is a national or regional marketing authorization, reviewing the product as sold in that market; WHO prequalification (WHO PQ) serves international procurement and supply, and its review dimensions are organized around fitness for procurement. The two are different in evidentiary type, and therefore different in dossier position: the former serves as a marketing-authorization-type reference, the latter fits better as supporting material on performance and quality systems. Writing them together as a blanket claim of EMA and WHO approval leaves the reviewer unable to determine which country and which decision corresponds to which version of the declared product, and the file will be queried for precisely that ambiguity.

Insight 4: reference-country evidence affects review intensity, not procedure or timelines.

However complete the reference-country material, the procedure still follows the current TUPA: 66 working days for Class III/IV, 44 working days for Class II, 22 working days for Class I, and 30 working days for IVD; the Observaciones response window is 30 working days (specific article numbers pending verification; official publications prevail). The reliance pathway saves time and round trips in technical argumentation, not procedural time itself. Total project duration has no statutory basis, and we estimate on a practical estimate basis at 4–8 months.

4. Practical recommendations

1. Produce an evidence matrix: list each reference-country approval (national or regional marketing authorization, WHO PQ and similar), the corresponding product models, approval dates, approval scope and the differences against the currently declared version.
2. Make differences explicit: where models, intended use or the manufacturing site differ, submit a difference comparison table with supplementary argument; do not expect the reviewer to reconstruct it.
3. Keep local documents separate: file reference-country approvals as independent annexes and compile the local technical report and essential-principles checklist separately, avoiding any impression that overseas documents replace local argument.
4. Lock versions: before submission, check every reference of the approval certificates by version number and date against the dossier, preventing self-contradictory versions within one file.
5. Match translations: the Spanish translations of reference-country approvals must correspond item by item to the originals, keeping product names and model spelling unchanged.
6. Keep secondary information out of the dossier: Comunicado N° 009-2026 (clinical evaluation reports), issued by DIGEMID on 2026-07-05, and Comunicado N° 011-2026 (registration and re-registration requirements), issued on 2026-08-19, come from industry databases; the numbers and dates are pending first-hand verification, serve as internal reference only, and must not be written into submission documents.

5. Verification checklist

□ It has been confirmed that reference-country approvals are reliance-type evidence and do not constitute an exemption from local registration

□ Triple identity has been checked item by item: same product, same intended use, same manufacturing site

□ A comparison table and supplementary argument have been prepared for all difference points

□ The essential-principles conformity checklist and technical report have been compiled under D.S. N° 003-2020-SA

□ The evidentiary positioning of EMA and high-surveillance authority approvals versus WHO PQ has been distinguished

□ Procedural clocks have been registered by risk level (22 / 44 / 66, IVD 30 working days) with the 30 working days response window reserved

□ DIGEMID communications from secondary sources have been excluded from submission documents

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides registration support in Peru for manufacturers, importers and authorized representatives, including reliance evidence mapping and dossier compilation. Contact: info@grzanglobal.com